AAAAI: GLP-1 Receptor Agonists Linked to Reduction in Asthma Exacerbation Risk

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 6, 2026.

via HealthDay

FRIDAY, March 6, 2026 -- Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with reduced asthma exacerbation risk among individuals with overweight or obesity, without diabetes, according to a study presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology, held from Feb. 27 to March 2 in Philadelphia.

Ruchi Patel, M.D., from Rutgers New Jersey Medical School in Newark, and colleagues used data from the global collaborative network in TriNetX to compare asthma exacerbation rates during a three-year period between those initiating a GLP-1 receptor agonist and matched controls without GLP-1 receptor agonist exposure.

The overweight, obese, and morbidly obese cohorts included 710 patients, 1,515 patients, and 1,249 patients, respectively, after propensity score matching. The researchers found that GLP-1 initiation was associated with a reduced risk for asthma exacerbations in the overweight group, with a risk ratio of 0.748 and a risk difference of 14.6 percent. GLP-1 receptor agonist initiation was associated with a reduced risk for exacerbation in the obese group, with a risk ratio of 0.790 and a risk difference of 12.2 percent. GLP-1 receptor agonist initiation was associated with a reduced risk for exacerbation in the morbidly obese group, with a risk ratio of 0.780 and risk difference of 13.3 percent.

"Asthma exacerbations can be disruptive for patients, especially those living with obesity, who often have fewer effective treatment options," Patel said in a statement. "Our findings suggest that GLP-1 receptor agonists may be associated with fewer asthma exacerbations in nondiabetic patients, pointing to a promising new direction that could ultimately improve day-to-day asthma control and quality of life."

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-07 01:38

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords